TEVA Teva Pharmaceutical Industries Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: TEVA

Price (delayed)

$11.21

Market cap

$12.45B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.95

Enterprise value

$32.84B

Highlights
The debt has declined by 12% year-on-year and by 3.7% since the previous quarter
TEVA's quick ratio is up by 7% from the previous quarter and by 7% YoY
TEVA's net income has surged by 73% year-on-year but it has dropped by 71% since the previous quarter
Teva Pharmaceutical Industries's EPS has surged by 73% YoY but it has shrunk by 73% QoQ
Teva Pharmaceutical Industries's equity has decreased by 12% YoY and by 3.3% QoQ
TEVA's revenue is down by 5% year-on-year
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Peers: PFE MRK

Key stats

What are the main financial stats of TEVA
Market
Shares outstanding
1.11B
Market cap
$12.45B
Enterprise value
$32.84B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.38
Price to sales (P/S)
0.81
EV/EBIT
N/A
EV/EBITDA
83.57
EV/Sales
2.13
Earnings
Revenue
$15.43B
EBIT
-$937M
EBITDA
$393M
Free cash flow
$476M
Per share
EPS
-$0.95
Free cash flow per share
$0.43
Book value per share
$8.14
Revenue per share
$13.9
TBVPS
$18.37
Balance sheet
Total assets
$45.93B
Total liabilities
$36.1B
Debt
$22.45B
Equity
$9.04B
Working capital
$1.17B
Liquidity
Debt to equity
2.48
Current ratio
1.11
Quick ratio
0.59
Net debt/EBITDA
51.9
Margins
EBITDA margin
2.5%
Gross margin
47.8%
Net margin
-6.8%
Operating margin
-7.1%
Efficiency
Return on assets
-2.2%
Return on equity
-10.8%
Return on invested capital
-3.1%
Return on capital employed
-2.7%
Return on sales
-6.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TEVA stock price

How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
1.08%
1 week
4.86%
1 month
60.14%
1 year
12.21%
YTD
39.95%
QTD
49.07%

Financial performance

How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$15.43B
Gross profit
$7.38B
Operating income
-$1.1B
Net income
-$1.05B
Gross margin
47.8%
Net margin
-6.8%
TEVA's net income has surged by 73% year-on-year but it has dropped by 71% since the previous quarter
The net margin has surged by 72% year-on-year but it has dropped by 70% since the previous quarter
TEVA's operating income has soared by 63% YoY
The operating margin has soared by 61% YoY

Growth

What is Teva Pharmaceutical Industries's growth rate over time

Valuation

What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
1.38
P/S
0.81
EV/EBIT
N/A
EV/EBITDA
83.57
EV/Sales
2.13
Teva Pharmaceutical Industries's EPS has surged by 73% YoY but it has shrunk by 73% QoQ
TEVA's price to book (P/B) is 38% higher than its 5-year quarterly average of 1.0 and 38% higher than its last 4 quarters average of 1.0
Teva Pharmaceutical Industries's equity has decreased by 12% YoY and by 3.3% QoQ
The P/S is 35% above the last 4 quarters average of 0.6 and 16% above the 5-year quarterly average of 0.7
TEVA's revenue is down by 5% year-on-year

Efficiency

How efficient is Teva Pharmaceutical Industries business performance
TEVA's ROE has plunged by 77% from the previous quarter but it has soared by 72% YoY
Teva Pharmaceutical Industries's return on assets has surged by 72% YoY but it has shrunk by 69% QoQ
Teva Pharmaceutical Industries's return on sales has surged by 65% YoY
The company's return on invested capital has surged by 65% YoY

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Teva Pharmaceutical Industries financials performed over time
The total assets is 27% greater than the total liabilities
Teva Pharmaceutical Industries's current ratio has increased by 10% YoY and by 3.7% QoQ
TEVA's quick ratio is up by 7% from the previous quarter and by 7% YoY
The debt is 148% greater than the equity
Teva Pharmaceutical Industries's equity has decreased by 12% YoY and by 3.3% QoQ
The debt has declined by 12% year-on-year and by 3.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.